GlassScriptPhysician profile
Michelle Lauer
NPI 1013483627
$1,535.89
in general payments reported to CMS, 2019-2025
18 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $152 · 2023: $567 · 2024: $249 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.81 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $238.01 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $195.30 | 2022-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $163.80 | 2023-2024 | Spravato, Invega Sustenna, Invega |
| Abbvie INC. | $139.57 | 2021-2025 | |
| Alkermes, INC. | $129.88 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Jazz Pharmaceuticals INC. | $79.48 | 2022 | |
| Neurocrine Biosciences, INC. | $79.04 | 2023-2024 | Ingrezza |
| Tris Pharma INC | $51.26 | 2023-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $45.52 | 2023-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $26.01 | 2024 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $24.62 | 2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $23.63 | 2024 | |
| Corium, LLC | $23.21 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $21.78 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $18.04 | 2022 | |
| Lundbeck LLC | $14.32 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.